Compare UK & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UK | VRAX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3M | 1.5M |
| IPO Year | 2020 | 2021 |
| Metric | UK | VRAX |
|---|---|---|
| Price | $1.78 | $1.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.5K | ★ 151.8K |
| Earning Date | 11-03-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.10 |
| 52 Week High | $5.90 | $13.19 |
| Indicator | UK | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 42.05 | 24.02 |
| Support Level | $1.63 | $0.16 |
| Resistance Level | $2.22 | $3.01 |
| Average True Range (ATR) | 0.19 | 0.28 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 36.76 | 1.53 |
Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. Company provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has two operating segments: Workspace membership, and Other services. The Workspace membership segment generates the majority of the company's revenue.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.